WO2003043580A3 - Procede pour identifier et valider des cibles de medicament potentielles - Google Patents

Procede pour identifier et valider des cibles de medicament potentielles Download PDF

Info

Publication number
WO2003043580A3
WO2003043580A3 PCT/US2002/037146 US0237146W WO03043580A3 WO 2003043580 A3 WO2003043580 A3 WO 2003043580A3 US 0237146 W US0237146 W US 0237146W WO 03043580 A3 WO03043580 A3 WO 03043580A3
Authority
WO
WIPO (PCT)
Prior art keywords
identifying
drug targets
validating
methods
potential drug
Prior art date
Application number
PCT/US2002/037146
Other languages
English (en)
Other versions
WO2003043580A2 (fr
Inventor
Tsvika Greener
Avishai Levy
Yuval Reiss
Danny Ben-Avraham
Iris Alroy
Original Assignee
Proteologics Inc
Tsvika Greener
Avishai Levy
Yuval Reiss
Danny Ben-Avraham
Iris Alroy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Inc, Tsvika Greener, Avishai Levy, Yuval Reiss, Danny Ben-Avraham, Iris Alroy filed Critical Proteologics Inc
Priority to CA002468107A priority Critical patent/CA2468107A1/fr
Priority to JP2003545261A priority patent/JP2005525790A/ja
Priority to AU2002352797A priority patent/AU2002352797A1/en
Priority to IL16206202A priority patent/IL162062A0/xx
Priority to EP02789751A priority patent/EP1456647A4/fr
Publication of WO2003043580A2 publication Critical patent/WO2003043580A2/fr
Publication of WO2003043580A3 publication Critical patent/WO2003043580A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

La présente invention concerne des procédés pour identifier et valider des cibles de médicament potentielles. Un aspect de cette invention concerne un procédé systématique pour créer une base de données de séquences de protéines ou d'acides nucléiques associés, avec des annotations concernant des associations potentielles des séquences à des maladies, ainsi qu'un procédé pour tester les associations potentielles à des maladies au moyen d'un dosage biologique et pour valider cette association à des maladies en diminuant l'expression de la séquence cible ou en augmentant l'expression de la séquence cible.
PCT/US2002/037146 2001-11-19 2002-11-19 Procede pour identifier et valider des cibles de medicament potentielles WO2003043580A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002468107A CA2468107A1 (fr) 2001-11-19 2002-11-19 Procede pour identifier et valider des cibles de medicament potentielles
JP2003545261A JP2005525790A (ja) 2001-11-19 2002-11-19 潜在的薬物ターゲットを同定及びバリデートする方法
AU2002352797A AU2002352797A1 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets
IL16206202A IL162062A0 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets
EP02789751A EP1456647A4 (fr) 2001-11-19 2002-11-19 Procede pour identifier et valider des cibles de medicament potentielles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33170101P 2001-11-19 2001-11-19
US60/331,701 2001-11-19

Publications (2)

Publication Number Publication Date
WO2003043580A2 WO2003043580A2 (fr) 2003-05-30
WO2003043580A3 true WO2003043580A3 (fr) 2004-04-15

Family

ID=23295003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037146 WO2003043580A2 (fr) 2001-11-19 2002-11-19 Procede pour identifier et valider des cibles de medicament potentielles

Country Status (7)

Country Link
US (1) US20030194725A1 (fr)
EP (1) EP1456647A4 (fr)
JP (1) JP2005525790A (fr)
AU (1) AU2002352797A1 (fr)
CA (1) CA2468107A1 (fr)
IL (1) IL162062A0 (fr)
WO (1) WO2003043580A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049607A1 (en) * 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
WO2005042708A2 (fr) * 2003-10-27 2005-05-12 Rosetta Inpharmatics Llc Procede pour designer des arnsi pour l'extinction de genes
WO2008008336A2 (fr) * 2006-07-11 2008-01-17 Avalon Pharmaceuticals, Inc. Identification chimio-séléctive de produits thérapeutiques
WO2018168777A1 (fr) * 2017-03-13 2018-09-20 学校法人関西学院 Agent prophylactique ou thérapeutique pour la fibrose kystique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119462A1 (en) * 2000-07-31 2002-08-29 Mendrick Donna L. Molecular toxicology modeling
US6470277B1 (en) * 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6278039B1 (en) * 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
EP1029072A4 (fr) * 1997-11-06 2004-04-07 Hutchinson Fred Cancer Res Procede d'identification de cibles de medicaments
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
EP1115872A2 (fr) * 1998-08-07 2001-07-18 Onyx Pharmaceuticals, Inc. Polypeptide chp, un ligand du pak65
AU767507B2 (en) * 1998-08-28 2003-11-13 New York University Novel ubiquitin ligases as therapeutic targets
AU6158799A (en) * 1998-10-13 2000-05-01 Onyx Pharmaceuticals, Inc. Novel cell signaling polypeptides and nucleic acids
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
WO2000050445A1 (fr) * 1999-02-26 2000-08-31 Oklahoma Medical Research Foundation Nouveau compose de complexe suppresseur de tumeur de von hippel-lindau et scf ubiquitine ligase
WO2000058472A2 (fr) * 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Adn isole codant pour des regulateurs cullin roc1 et roc2, proteines isolees codees par ledit adn. procedes d'utilisation associes
IL151928A0 (en) * 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
AU2001257421A1 (en) * 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
WO2003022987A2 (fr) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Procedes de diagnostic de l'infection par l'hepatite c, compositions et procedes de criblage de modulateurs de l'infection par l'hepatite c
JP2005531491A (ja) * 2001-10-18 2005-10-20 ジェネンテック・インコーポレーテッド 癌の治療のための組成物と方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6470277B1 (en) * 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US20020119462A1 (en) * 2000-07-31 2002-08-29 Mendrick Donna L. Molecular toxicology modeling

Also Published As

Publication number Publication date
JP2005525790A (ja) 2005-09-02
IL162062A0 (en) 2005-11-20
AU2002352797A1 (en) 2003-06-10
WO2003043580A2 (fr) 2003-05-30
CA2468107A1 (fr) 2003-05-30
EP1456647A2 (fr) 2004-09-15
EP1456647A4 (fr) 2006-10-18
US20030194725A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2004052175A3 (fr) Procedes pour l'identification rapide de pathogenes chez les humains et chez les animaux
SE0003286D0 (sv) Method and kit for human identification
WO2007030531A3 (fr) Reactifs d'essai et d'imagerie moleculaire du cancer du foie
WO2003062462A3 (fr) Methode permettant d'isoler des acides nucleiques et des proteines contenus dans un echantillon unique
WO2002040717A3 (fr) Procedes reposant sur l'utilisation de cellules in vitro pour la validation biologique et le criblage pharmacologique d'entites chimiques et de produits biologiques
WO2003086308A3 (fr) Compositions et procedes pour le diagnostic et le traitement de l'infection du virus de l'herpes simplex
WO2004007743A3 (fr) Utilisation d'acides nucleiques cpg dans les maladies a prions
EP2287177A3 (fr) Antigènes I + II de Streptococcus agalactiae
WO2002084250A3 (fr) Procedes de detection par spectrometrie de masse et quantification de proteines cibles specifiques dans des echantillons biologiques complexes
WO2008018905A8 (fr) Procédé permettant de prédire les réponses des systèmes biologiques
ATE335852T1 (de) Happier mapping
WO2002093129A3 (fr) Methodes d'analyse des interactions entre proteines dans des cellules vivantes et entieres
WO2005121374A3 (fr) Analyse moleculaire de follicules pileux pour des maladies
WO2005067648A3 (fr) Profilage spatial multiplex d'expression genique
WO2002063271A3 (fr) Analyse au moyen de sondes fondees sur l'activite
EP1318472A3 (fr) Procédé d'analyse de données d'expression moléculaire et réseaux biologiques
WO2000070340A3 (fr) Materiaux et procedes se rapportant au diagnostic de maladie
WO2003043580A3 (fr) Procede pour identifier et valider des cibles de medicament potentielles
WO2005033330A3 (fr) Sondes fluorescentes pour test de liaison d'inhibiteur de proteine kinase
EP1283272A3 (fr) Méthodes et moyens d'évaluation d'une thérapie à base des inhibiteurs de l'enveloppe du VIH
WO2003016551A3 (fr) Proteine de liaison a l'acide salicylique codant des acides nucleiques, proteine de liaison a l'acide salicylique 2 (sabp2) et methodes d'utilisation associees
WO2002063951A3 (fr) Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique
WO2001042503A3 (fr) Appareil et methodes de criblage de medicaments
WO2002066982A3 (fr) Analyse de modifications et de demodifications de proteines avec des proteines apparentees a l'ubiquitine par fret (transfert d'energie de resonance par fluorescence)
ATE440968T1 (de) Verfahren zur diagnostizierung von aspirinunverträglichkeit

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003545261

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 162062

Country of ref document: IL

Ref document number: 2468107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002352797

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002789751

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002789751

Country of ref document: EP